Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Wednesday, May 14, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: Precision BioSciences is advancing its PBGENE-DMD gene editing therapy aimed at Duchenne Muscular Dystrophy patients with specific dystrophin mutations. The therapy has shown compelling preclinical evidence, which was highlighted at the ASGCT Annual Meeting. This development marks a significant step in the company's organic pipeline.
Price reaction · baseline $4.95 (2025-05-14 close) · hit after-hours · 2 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
-8.1%
day 1
-4.8%
day 3
-1.4%
Market Sentiment Analysis
POSITIVE FACTORS
PBGENE-DMD shows promising preclinical data.
It targets a significant patient population with Duchenne Muscular Dystrophy.
The approach is first-in-class and innovative.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– PBGENE-DMD is a first-in-class in vivo gene editing approach for the majority of Duchenne Muscular Dystrophy patients impacted by dystrophin mutations in the most common ‘hot spot’ region between exons 45-55 – – Final clinical candidate PBGENE-DMD demonstrates compelling preclinical data for
Frequently Asked Questions
What is PBGENE-DMD?
PBGENE-DMD is a first-in-class in vivo gene editing therapy for Duchenne Muscular Dystrophy.
What mutations does PBGENE-DMD target?
It targets dystrophin mutations in the common 'hot spot' region between exons 45-55.
Where was the preclinical evidence presented?
The preclinical evidence for PBGENE-DMD was highlighted at the ASGCT Annual Meeting.
What is the significance of PBGENE-DMD?
It represents a significant advancement in the treatment options for DMD patients.